Market and contract research organization IQVIA has published its Global Oncology Trends report for 2024, projecting a ...

The Bill & Melinda Gates Medical Research Institute (Gates MRI) has appointed Patrice Matchaba, as chief executive (CEO), ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. ASCO organizers ...

Ikena Oncology (Nasdaq: IKNA) has announced the discontinuation of its IK-930 program, as well as plans to slash its workforce by about 50%. Shares in the company rose by almost a fifth in pre-market ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application and granted Priority Review to inavolisib, an investigational, oral therapy, in combination with palbociclib (Ibrance ...

Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and ...

Dublin, Ireland-headquartered protein specialist Prothena announced that US pharma major Bristol Myers Squibb has obtained the exclusive global license for PRX019.

Less than two years after it was launched, San Francisco-based startup Cartography Biosciences has announced a deal with nearby biotech major, Gilead Sciences (Nasdaq: GILD).

Cambridge, USA-based Agios Pharmaceuticals (Nasdaq: AGIO) closed up more than 23% at $38.81 yesterday, after it revealed it has agreed to sell its rights to its 15% royalty on potential US net ...

US biotech Insmed (Nasdaq: INSM) yesterday released positive top-line results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase III trial to assess the efficacy, ...